Dr. Reddy's is a big Indian generic drugmaker.
Dr. Reddy's Laboratories Limited (RDY) is expected to report earnings on Friday, October 23, 2026, after the close. Consensus EPS estimate is $0.10.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-21 | FY2026 Q2 | $0.09 | $0.06 | -34.7% | $835.68M |
| 2026-05-12 | FY2026 Q1 | $0.09 | $0.06 | -33.3% | $785.89M |
| 2025-06-30 | FY2025 Q2 | $0.21 | $0.20 | -6.7% | $997.48M |
| 2024-06-30 | FY2024 Q2 | $0.19 | $0.20 | +4.0% | $920.72M |
| 2023-06-30 | FY2023 Q2 | $0.15 | $0.21 | +36.4% | $821.16M |
| 2022-09-30 | FY2022 Q3 | $0.56 | $0.16 | -71.6% | $9.69M |
| 2022-06-30 | FY2022 Q2 | $0.51 | $0.18 | -64.8% | $660.23M |
RDY has beaten consensus EPS in 2 of its last 7 reported quarters.
Highlights from RDY's Jul 21 report: EPS of $0.06 — a sharp miss vs the $0.09 estimate (-35%); revenue of $836M — in line with the $851M consensus. Focus now shifts to US generics pricing and Russia.
RDY pays a annual dividend, currently yielding 0.71%.
| Ex-dividend date | Amount | Paid |
|---|---|---|
| 2026-07-24 | $0.0834 | 2026-08-05 |
| 2025-07-25 | $0.0915 | 2025-08-06 |
| 2024-07-30 | $0.4762 | 2024-08-12 |
| 2023-07-07 | $0.488 | 2023-08-11 |
| 2022-07-08 | $0.387 | 2022-07-11 |
| 2021-07-09 | $0.3365 | 2021-08-11 |